Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The funds will help advance inobrodib, a first-in-class p300/CBP inhibitor with a completed a phase 2 study.
read more
The Oncologic Drugs Advisory Committee failed to reach a majority vote in favor of the benefit–risk profile of AstraZeneca's camizestrant.
read more
Already approved for obstructive HCM, Cytokinetics announced positive topline results from a phase 3 trial of aficamten in non-obstructive HCM.
read more
The drugmaker will cut 220 jobs as part of the planned closure of a production site by the end of 2028.
read more
Veppanu reduced disease progression and death by 43% compared to fulvestrant.
read more
The facility will focus on manufacturing APIs for solid dosage tablets and capsules as part of a plan to produce all key medicines within the country.
read more
The drugs include metformin, metformin extended release, Invokana (an SGLT2 inhibitor for type 2 diabetes) and blockbuster Xarelto (a blood thinner).
read more
Ajax's lead candidate is an oral, Type II JAK2 inhibitor that uses a unique mode of binding for potentially deeper and more durable disease control.
read more
Idvynso demonstrated non-inferior efficacy compared to the three-drug regimen in a phase 3 trial.
read more
If approved, the drug will be the first oral GLP-1 RA that provides superior glycemic efficacy in pediatric patients with T2 diabetes.
read more
Three psychedelic drugs will receive national priority vouchers from the FDA next week.
read more
The phase 1 trial led to median hsCRP reductions of more than 85% when patients took daily doses.
read more
Among its most promising drugs is oral ribupatide, a once-daily pill entering phase 3 trials in China.
read more
Schwartz, an ex deputy surgeon general, will take over the role if she receives Senate approval, which could take months.
read more
The FDA has granted full approval to Filspari to reduce proteinuria in focal segmental glomerulosclerosis without nephrotic syndrome.
read more